Grand Pharma, a pharmaceutical company, led a $55m Series C round in InnovHeart, a developer of transcatheter mitral valve replacement equipment, with participation from Genextra, Panakes Partners and Indaco Venture Partners. "Interventional treatment for mitral regurgitation is considered to be one of the most challenging areas in the field of structural heart disease, yet also represents huge market potential, estimated to reach $17.4bn globally in future years. This strategic agreement will provide InnovHeart with resources that will accelerate the development of the trans-septal version of the Saturn system into First-in-Human clinical trials, as well as access to the dynamic Chinese structural heart market," Keith D. Dawkins, InnovHeart Chairman of Board of Directors.